Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease.

137 , 138 The LoDoCo2 trial found that colchicine treatment conferred a 41% decrease in the composite endpoint of cardiovascular death, MI, stroke, or ischemia-driven coronary revascularization (HR 0.69; 95% CI [0.57–0.83]), although a nonsignificant trend towards increased non-cardiovascular death in the treatment group (HR 1.51; 95% CI [0.99– 2.31]) was also noted. 138 The COLCOT trial examined colchicine treatment in patients with recent MI and demonstrated a decreased risk of the composite endpoint of cardiovascular death, cardiac arrest, MI, str

also in 5,406 other papers

For example, analysis of the FOURIER trial demonstrated a significant trend in the control group between increased hs-CRP and event rates (cardiovascular death, MI, stroke, all-cause mortality, and coronary revascularization [p for trend <0.0001]). 130 With adjustment for LDL cholesterol achieved during the trial and other confounders, higher baseline hs-CRP was significan

also in 9,775 other papers